1) Parvaneh Sadeghi works as a laboratory technician in Research & Development at Novo Nordisk in Denmark. 2) Novo Nordisk is a large pharmaceutical company headquartered in Denmark that was formed through mergers and has a history in insulin production dating back to the 1920s. 3) The document provides an overview of Novo Nordisk's strategy, operations, and initiatives to address diabetes as a global challenge through programs like Changing Diabetes and Cities Changing Diabetes.

1. PARVANEH SADEGHI
Parvaneh is a laboratory technician in
Research & Development in Novo Nordisk
Denmark
ComCase ‘15
Kickoff event
CBS, 27 November 2014
Mike Rulis & Charlotte Ersbøll

2. Novo Terapeutisk
Laboratorium 1925
Merger of Novo Industri
and Nordisk Gentofte 1989
Novo Nordisk 2000Nordisk
Insulinlaboratorium
1923
Novozymes 2000
The short version of our history
2Novo Nordisk - Corporate Presentation

3. 14th largest pharmaceutical company in terms of sales (2013)
3
-
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
BillionUSdollar

4. Sales
4

5. Our global presence
5Novo Nordisk - Corporate presentation
3 strategic R&D centres
China, Denmark, US
5 Strategic production sites
Brazil, China, Denmark, France, US
5 Regional headquarters
China, Japan, Europe, IO,
North America
Global headquarters
Denmark
75 affiliates
Novo Nordisk markets its products in 180
countries worldwide

6. Employees by region
in 75 countries
We are more than 40,000 employees
6Novo Nordisk - Corporate presentation
1. Includes headquarter functions, R&D, production sites and sales office.

7. The objective of the Novo Nordisk Foundation is twofold:
• to provide a stable basis for the commercial and research activities conducted by the
companies within the Novo Group
• to award significant amounts for scientific and humanitarian purposes
The Novo Nordisk Foundation approves the allocation of profits within Novo A/S.
Novo A/S is a holding company wholly-owned by the Novo Nordisk Foundation. Novo A/S
manages the Foundation’s broad portfolio of financial assets through investments in the
life science area.
Novo A/S is the majority shareholder in the listed companies Novo Nordisk
A/S and Novozymes A/S.
Novo A/S holds 25.5% of the total share capital and 73% of the total number
of votes. Other shareholders hold 74.5% of the total share capital and 27%
of the total number of votes.
Novo Nordisk A/S is listed on NASDAQ OMX Copenhagen and New York Stock
Exchange.
Ownership structure
7Novo Nordisk - Corporate Presentation

8. Novo Nordisk’s corporate strategy
8
Core capabilities
Expand leadership in
DIABETES
Pursue leadership in
HAEMOPHILIA
Establish presence in
OBESITY
Expand leadership in
GROWTH DISORDERS
Strategic priorities
Novo Nordisk Way
Engineering,
formulating,
developing and
delivering
protein-based
treatments
Building and
maintaining a
leading position
in
emerging
markets
Deep disease
understanding
Efficient large-
scale
production of
proteins
Planning and
executing
global launches
of new
products

9. The Novo Nordisk Way
How we want to achieve success
Our ambition is to strengthen our
leadership in diabetes.
We aspire to change possibilities in
haemophilia and other serious
chronic conditions.
Our key contribution is to discover
and develop innovative biological
medicines and make them accessible
to patients throughout the world.
9

10. The Triple Bottom Line
Introduction course 10
Patients

11. The diabetes pandemic
11
People waiting at a diabetes
clinic in Tanzania
VL45 presentation

12. The global diabetes challenge
12

13. • Risk factors include:
• Urbanisation and rapid socio-economic
transition – the ‘mismatch theory’
• Obesity
• Poor diet
• Physical inactivity
• Advancing age
• Family history in diabetes
• Ethnicity
• Gestational diabetes – risk for both mother
and child
Why the explosive growth in type 2 diabetes?
13

14. 14
The ‘Rule of Halves’
a story of missed opportunities
Actual rates of diagnosis, treatment, targets and outcomes vary in different countries

15. Diabetes – a European snapshot
15
1 in 3 people with
diabetes do not
know they have it
1 in 12 adults
have diabetes
Diabetes costs 116 billion euros in
direct health expenditures in Europe
in 2014

16. Use Novo Nordisk’s diabetes products every day
16
24.3

17. Novo Nordisk Changing Diabetes
KOFI ANNAN and LISE KINGO
Setting the agenda for change
2013 IDLF, Turkey
17

18. 18
Changing Diabetes®
Start with “why”
• “People don't buy what you do; they
buy why you do it. And what you do
simply proves what you believe.”
• “If you hire people just because they
can do a job, they’ll work for your
money. But if you hire people who
believe what you believe, they’ll work
for you with blood and sweat and
tears.”
Simon Sinek, Author of “Start with why”
18

19. Changing Diabetes® is our promise to improve health
and quality of life
Expand access to
affordable care worldwide
Improve health outcomes
for people with diabetes
• DAWN2
• Changing Diabetes®
barometer
• Healthcare professionals
and patient training
• Action on Diabetes
• Changing Diabetes®
40by20 Patient Ambition
• LDC pricing policy
• Changing Diabetes® at
the Base of the Pyramid
• Changing Diabetes® in
Children
Prevent diabetes in
future generations
• Changing Diabetes® in
Pregnancy
• Changing Future Health
Drive awareness
and public policy
• World Diabetes Day
• Changing Diabetes®
Leadership Forums
• Changing Diabetes®
Village
• Team Novo Nordisk
19

20. Changing Diabetes®
goes hand-in-hand with our business
Changing Diabetes® plans
take their starting point in
diabetes rule of halves
with prioritised Changing
Diabetes® actions where
societal needs intersect
with business opportunity
20

21. Presentation title Date 21

22. Novo Nordisk
Access to Health
Strategy
Differential Pricing
for LDCs
2011
World Partner
Project
Oxford Health
Alliance
Denmark and
Russia
Support to UN
Resolution
on Diabetes
20142001
Building on 10 years of Changing Diabetes®
New York
China

23. 23
Changing Diabetes®
A Platform for strengthening stakeholder relations

24. UN adoption of
Resolution on
diabetes
UN High-Level
meeting on NCDs
2006 2007 2008 2009 2010 2011 2012 2013 2014
NCDs recognised in
Rio+20 outcome
document
Novo Nordisk
World events
Europe Turkey Europe, Latin
America & Pakistan
MENA & AfricaChinaRussiaUSA
First UN
observed World
Diabetes Day
WHO target on
NCDs
2015
Changing Diabetes® Leadership Forums
The journey
Post 2015:
NCDs in UN Sustainable
Development Goals
24

25. Leadership Forums put
change on the agenda
Since 2007, we have convened 9 international and
52 national diabetes leadership forums.
13,000 high-level policy stakeholders and decision
makers have engaged in the question of changing
diabetes in 40 countries
Pursuing our goal to push diabetes to the top of
the political and healthcare agenda around the
world
25
Source: Novo Nordisk internal documents.
LARS REBIEN SØRENSEN, HRH CROWN PRINCE FREDERIK OF DENMARK,
PRESIDENT BILL CLINTON, HH SHEIKH RASHID BIN HAMDAN AL
MAKTOUM and MAKTOUM HASSAN ALI AL QASSAM.
MENA Forum 2010 in Dubai, United Arab Emirates

26. 17 countries
International
Diabetes
Federation (IDF)
Steno
Diabetes
Center
International
Alliance of Patient
Organizations
(IAPO)
15,438 respondents
8,596 people with diabetes
2,057 family members
4,785 diabetes care professionals
Patient organisations and
policy makers
1. Nicolucci A, et al. Diabet Med 2013;30:767–77; 2. Kovacs Burns K, et al. Diabet Med 2013;30:778–88
3. Holt RIG, et al. Diabet Med 2013;30:789–98
DAWN2™ - the world’s largest psychosocial study
We start with the patient
26

27. The DAWN2™ study revealed that
• 19% of people with diabetes feel
discriminated against because of
their condition
• 37% of family members feel
frustrated because they do not
know how best to help their
relative with diabetes
• 45% of people with diabetes
experience diabetes-related
distress
VERÓNICA RUBIO FRANCO WITH HER CHILDREN
Mexico
Verónica had gestational diabetes
and now has type 2 diabetes
27

28. Team Novo Nordisk:
racing to change
diabetes
Team Novo Nordisk is a world-class sports
programme for athletes with diabetes.
Their mission is to educate, empower and
inspire people affected by diabetes. Team Novo
Nordisk shows that it is possible for people with
diabetes to live full lives and achieve ambitious
personal goals.
Team Novo Nordisk
Professional cycling team
28

29. The Fight against
Urban Diabetes
29

30. Urban health: Emerging & untapped opportunity
Many cities face a triple threat:
• Infectious diseases
• Chronic, non-communicable diseases
• Accidents, injuries, road accidents,
violence, and crime
Dr Margaret Chan, Director-General, WHO
One of my pet peeves is that obesity and
diabetes – and their connection to community
design – are virtually ignored by health
scientists in the world of environmental advocacy,
who remain almost exclusively focused on pollution
Dr Richard Jackson, MD, MPH
Designing Healthy Communities, Atlantic Cities

31. The rise of city mayors
“City leaders also govern the places where
this century's most intractable problems
play out – and where solutions are most
likely to be found.”
“The White House Would Be a Step Down.
No elective office can match the New York
City mayoralty as a source of direct action
to improve everyday life.”
“New York's next mayor needs to be
ready to go global. “

32. Launched in Mexico City 25 March
32
In Mexico
City we
have the
building
blocks to
tackle
urban
diabetes.”

33. The new frontline
• My argument today is that these two
trends are related: global cities and global
diabetes
• We believe that focusing on cities is the
new frontline of the fight against diabetes
• What we need now is a wake-up call
• We need to make sure that urban diabetes
is always on the agenda when people take
decisions about managing cities
• We want to put this issue right to the top
of the agenda of the global healthcare
community
• We need a global fight against urban
diabetes
- Lars Rebien Sørensen, Mexico City

34. 34
Public-private partnerships
Global fight
against urban
diabetes
Urban diabetes is
on the rise
Cities Changing Diabetes is our response
Activities
• Map the diabetes challenge in
selected big cities across the world
• Share learning and best practices
on how to break the Rule of Halves
• Implement action plans with local
partners
México City
28 March 2014
Copenhagen
22 August 2014
City partners
Houston
3 November 2014
Tianjin
13 November 2014
Shanghai
14 November 2014
Cities Changing Diabetes aims to break the Rule of Halves
and stop urban diabetes from ruining millions of lives

35. First-wave cities
Need, business, opportunity, global spread
35
By 2025, 136 new cities are
expected to enter the top 600,
all of them from the
developing world and
overwhelmingly—100 new
cities—from China.
McKinsey Global Institute
Mexico City
Houston
Copenhagen
Tianjin

36. 36

38. TheApisbulllogoisaregisteredtrademarkofNovoNordiskA/S
38